Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 20 04:00PM ET
1.96
Dollar change
-0.06
Percentage change
-2.97
%
Index- P/E- EPS (ttm)-7.36 Insider Own14.04% Shs Outstand1.60M Perf Week3.16%
Market Cap3.05M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.38M Perf Month-7.98%
Income-11.78M PEG- EPS next Q- Inst Own11.99% Short Float9.29% Perf Quarter-37.18%
Sales0.01M P/S304.67 EPS this Y- Inst Trans-25.73% Short Ratio5.29 Perf Half Y-70.89%
Book/sh1.70 P/B1.15 EPS next Y- ROA-102.49% Short Interest0.13M Perf Year-75.11%
Cash/sh1.08 P/C1.81 EPS next 5Y- ROE-141.73% 52W Range1.63 - 32.85 Perf YTD-81.52%
Dividend Est.- P/FCF- EPS past 5Y21.41% ROI-432.49% 52W High-94.03% Beta-0.39
Dividend TTM- Quick Ratio4.30 Sales past 5Y86.87% Gross Margin-3966.67% 52W Low20.25% ATR (14)0.25
Dividend Ex-Date- Current Ratio4.30 EPS Y/Y TTM68.32% Oper. Margin-123633.33% RSI (14)44.39 Volatility12.90% 13.07%
Employees1 Debt/Eq0.00 Sales Y/Y TTM-60.00% Profit Margin-196350.00% Recom3.00 Target Price1125.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q86.71% Payout- Rel Volume0.40 Prev Close2.02
Sales Surprise- EPS Surprise-14.29% Sales Q/Q- Earnings- Avg Volume24.22K Price1.96
SMA20-11.22% SMA50-10.21% SMA200-71.62% Trades Volume9,699 Change-2.97%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Resumed Wells Fargo Overweight $3
Oct-11-24 08:57AM
May-15-24 10:55PM
Apr-08-24 12:52PM
Dec-18-23 07:57AM
Nov-14-23 07:56AM
07:30AM Loading…
07:30AM
Aug-14-23 04:05PM
Jun-29-23 07:00AM
May-25-23 05:00PM
May-10-23 07:00AM
May-03-23 08:30AM
Apr-26-23 12:30PM
Mar-30-23 07:00AM
Mar-29-23 05:30PM
Mar-07-23 07:00AM
04:01PM Loading…
Feb-28-23 04:01PM
Feb-17-23 05:47AM
Jan-09-23 08:30AM
Nov-29-22 09:01AM
Nov-28-22 04:01PM
Nov-14-22 07:00AM
Nov-08-22 08:30AM
Nov-07-22 08:00AM
Sep-21-22 08:30AM
Sep-07-22 08:30AM
Sep-06-22 08:00AM
Aug-24-22 03:00PM
Aug-15-22 07:00AM
Aug-08-22 08:50AM
Aug-04-22 05:00PM
09:31AM Loading…
Jul-06-22 09:31AM
Jun-30-22 07:07AM
Jun-27-22 08:00AM
Jun-01-22 08:30AM
May-26-22 05:01PM
May-16-22 07:30AM
May-12-22 11:48AM
May-10-22 08:30AM
May-09-22 08:30AM
May-02-22 04:31PM
08:30AM
Mar-30-22 07:30AM
Mar-22-22 01:58PM
Mar-16-22 08:30AM
Mar-08-22 04:05PM
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.